Eurand Granted FDA Approval for ZENPEP First and Only FDA-Approved Pancreatic Enzyme Product Clinically Tested in Patients Under 12 Years Old

August 28, 2009) - Eurand N.V., a specialty pharmaceutical company, today announced U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for ZENPEP™ (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions.

The details can be read here.